Cover Image
市場調查報告書

Caspase6:開發中產品分析

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 371946
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
Caspase6:開發中產品分析 Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2017
出版日期: 2017年06月20日 內容資訊: 英文 48 Pages
簡介

本報告提供以Caspase6為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Caspase6 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Conatus Pharmaceuticals Inc.
  • LG Life Science LTD.
  • New World Laboratories, Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0850TDB

Summary

According to the recently published report 'Caspase 6 - Pipeline Review, H1 2017'; Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Caspase-6 is an enzyme encoded by the CASP6 gene. It is involved in the activation cascade of caspases responsible for apoptosis execution. It cleaves poly (ADP-ribose) polymerase.

The report 'Caspase 6 - Pipeline Review, H1 2017' outlays comprehensive information on the Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal, Cardiovascular, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Oncology and Respiratory which include indications Huntington Disease, Alzheimer's Disease, Autoimmune Hepatitis, Colorectal Cancer, Hepatitis C, Hepatocellular Carcinoma, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Transplant Rejection, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Pancreatic Islet Transplant Rejection, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis and Renal Failure.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)
  • The report reviews Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Overview
    • Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Companies Involved in Therapeutics Development
    • Conatus Pharmaceuticals Inc
    • New World Laboratories Inc
  • Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Drug Profiles
    • ED-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emricasan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IDN-7314 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NWL-154 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Dormant Products
  • Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting
      • Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
      • Oct 03, 2016: Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting
      • May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
      • Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
      • Apr 15, 2016: Conatus Poster at EASL Meeting Today Addresses Safety of Caspase Inhibition in Cancer Treatment
      • Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting
      • Feb 03, 2016: FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis
      • Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis
      • Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
      • Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting
      • Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
      • Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
      • Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting
      • Sep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Conatus Pharmaceuticals Inc, H1 2017
  • Pipeline by New World Laboratories Inc, H1 2017
  • Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top